Organization (WHO) definition of maternal sepsis (suspected/ confirmed infection with evidence of end-organ damage). We assessed differences in the frequency, prevalence, and temporal trends of sepsis, patient and hospital characteristics, and hospital utilization measures (length of stay, direct hospital medical costs) and in-hospital mortality associated with sepsis. RESULTS: Of the more than 55 million delivery-associated hospitalizations, 13,129 and 45,550 were affected by sepsis based on the Sepsis-2 and WHO definitions, respectively. The rate of sepsis using old criteria was 2.4 vs. 8.3 per 10,000 using new criteria. The rate of sepsis increased during the study period under both definitions with annual percent increases of 6.7% (Sepsis-2) and 7.5% (WHO). In-hospital mortality rate among those with sepsis based on the WHO definition (3.1%) was lower than Sepsis-2 (9.4%). Hospital utilization was statistically significantly higher for Sepsis-2 (mean length of stay (LOS): 15 days; mean cost: $53,700) than for the WHO definition (mean LOS: 9 days; mean cost: $27,100; p<.0001). However, due to the increased number of cases maternal sepsis under the WHO definition, the estimated average annual cost of direct medical care for women with sepsis during delivery was higher for the WHO definition ($84.2 vs. $50.0 million). Regardless of the definition used, all clinical outcomes were significantly increased compared to delivery-associated hospitalizations unaffected by sepsis.
CONCLUSION:
The newer WHO definition classifies significantly more cases as delivery-associated sepsis, and despite capturing less severe cases, may allow an opportunity for more aggressive treatment in an effort to improve outcomes. OBJECTIVE: Many patients will require intravenous (IV) access during the course of pregnancy and peripherally inserted central catheters (PICCs) are commonly used to obtain long-term IV access. Pregnancy is associated with an altered immune response and is also a prothrombotic state; therefore, a theoretical safety concern surrounds the antenatal use of PICCs. The objective of this study was to assess the rate of complications associated with use of PICCs in pregnancy STUDY DESIGN: In order to assess the rate of complications associated with antenatal PICC use, a systematic review was performed by searching published literature for records discussing PICC use in pregnant or postpartum women. We performed a MEDLINE esearch through Pubmed, EMBASE, Scopus, the Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, CINAHLPlus, and Clinicaltrials.gov. We included studies with primary data regarding rates of maternal complications from PICC use (infectious, thromboembolic, mechanical failure, superficial thrombophlebitis). Meta-analysis was performed using STATA 12 with the METAN and METAPROP software routines. Pooled estimates with 95%CI were calculated using a random effects model after Freeman-Tukey Double Arcsite Transformation. RESULTS: After removal of duplicates, the primary search yielded 318 articles, with 5 being included for final analysis. The pooled rate of combined infectious and thromboembolic complications was 25% (95%CI 6-50%). Secondary outcomes showed that the pooled rate Poster Session IV ajog.org S542 American Journal of Obstetrics & Gynecology Supplement to JANUARY 2019 of infectious complications was 18% (95%CI 4-37%), thromboembolic complications 5% (95%CI 0-15%) and mechanical failure 7% (95%CI 3-12%). Only two studies reported on rates of superficial thrombophlebitis and analysis was unable to be performed. There was significant statistical heterogeneity between studies, for all outcomes except mechanical failure (I 2 ¼41.8%, p¼0.14). CONCLUSION: The data regarding complication rates due to PICC use in pregnancy are limited, and there is a high level of heterogeneity among existing studies. Overall, the risk of thromboembolic events appears low. The rate on infection associated with PICC use appears to have the most variability, ranging from 4-37%. This suggests that infection risk may be modifiable and further studies are needed to assess interventions that may lower this risk.
832 Universal screening of inherited thrombophilias to reduce venous thromboembolism risk in pregnancy: a decision analysis OBJECTIVE: Approximately 20-50% of venous thromboembolism (VTE) in pregnancy and postpartum are ultimately identified to have an inherited thrombophilia. As VTE remains one of the leading yet potentially preventable causes of severe maternal morbidity and mortality in the US, we employed a decision analytic model to evaluate if universal screening for thrombophilia would result in increased detection and decreased mortality in our obstetric population as a strategy to reduce VTE related maternal morbidity and mortality. STUDY DESIGN: A decision analytic model was used to compare three screening strategies: no screening, individual inherited thrombophilia screening (Factor V Leiden, Prothrombin gene mutation and Antithrombin III) or a comprehensive panel screening (a single screening panel designed to identify the above 3 thrombophilias). Probability estimates for relevant events and outcomes were obtained from the literature and utilized data specific to the obstetric patient population when available (Table 1) . For our base case analysis we applied our model to 3 million women to represent the number of new pregnancies annually and chose a VTE probability of 0.5/1000 pregnancies in unscreened, untreated women based on the most recently published American College of Obstetricians and Gynecologists clinical practice guidelines on thromboembolism and inherited thrombophilias. One-way sensitivity analyses were performed. RESULTS: After applying our model to 3 million women, universal screening using a comprehensive screening panel was the strategy that most significantly reduced the occurrence of VTE. The model was most impacted by the probability of Factor V Leiden heterozygosity in the population. Even with the most prevalent thrombophilias, the number need to screen to prevent a single VTE was 3,610 and 95,238 to prevent a maternal mortality from a VTE secondary to an undiagnosed thrombophilia (Table 2) . One-way sensitivity analyses demonstrated that even with a reduction in the frequency of VTE with thromboprophylaxis the number needed to screen was still unacceptably high. CONCLUSION: VTE is a leading cause of severe maternal morbidity and mortality in the United States and inherited thrombophilias account for 20-50% of VTE episodes in pregnancy. A universal screening strategy does reduce the number of VTE episodes and resultant maternal deaths in our model, however, the number needed to screen and treat to prevent a VTE or maternal death remains extremely high.
